Skip to main content

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Completed · Phase 1, Phase 2 · NCT03740529

Conditions: Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Small Lymphocytic Lymphoma

At a glance

Research payments reported, 2025
$1.7M
U.S. investigators named
32
Sites paid
33
Planned or actual enrollment
803

About the trial

Sponsor
Loxo Oncology, Inc. (with Eli Lilly and Company)
Tested
Pirtobrutinib (drug), Venetoclax (drug), Rituximab (drug)
Dates
Started 2019-03-15; completion 2025-12-23
Results posted
Not yet

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

From ClinicalTrials.gov, last updated 2026-01-27. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $1.7M in research payments for this study in 2025 (59 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.